Grounded in peer-reviewed science
NeuroQuantix is built on 300+ peer-reviewed studies spanning 44 years of movement disorder research. Every metric, every diagnostic rule, and every clinical threshold is traceable to published literature with documented evidence provenance.
Featured Publication
Movement Disorders Clinical Practice · 2025; 12(11): 1742–1755
Clinical Applications and Measurement Properties of the Digitized Archimedes Spiral Drawing Test: A Scoping Review
Wang S, Schwirtlich T, McLaughlin D, Beestrum M, Heinemann AW
A comprehensive scoping review of 120 studies (screened from 1,407 citations across six databases) evaluating the digitized Archimedes spiral drawing test as a clinical outcome measurement instrument. The review maps the field's evidence on reliability, validity, and responsiveness across PD, ET, and emerging applications — and identifies the standardization gaps that NeuroQuantix is designed to address.
Strong Reliability
ICC values of 0.74–0.97 across 14 test–retest studies in PD and ET populations. Digital measures showed lower variability than expert visual ratings.
Validated Against Gold Standards
Strong correlations with accelerometry (r = 0.7–0.9), FTM tremor ratings (R² = 88.9%), and clinical tremor scales across 45 validity studies.
Sensitive to Interventions
Demonstrated responsiveness to L-dopa, ethanol, MR-guided focused ultrasound thalamotomy, and deep brain stimulation across 6 studies.
Gap: Standardization
Significant variability in devices, drawing tasks, and analysis methods across studies. The review calls for harmonized protocols — exactly what NeuroQuantix provides.
Gap: Beyond PD & ET
Evidence for reliability and responsiveness outside PD/ET remains limited. NeuroQuantix addresses this with 23-condition differential profiles.
Gap: Reporting Standards
63.3% of studies did not specify speed/accuracy instructions. The review calls for standardized reporting — a core design principle of the NeuroQuantix protocol.
Evidence Foundation
The numbers behind the platform.
Canonical literature references mapped to metrics with structured evidence provenance
Across 12 functional domains — each with documented clinical relevance and literature backing
Evidence-graded (A through D) with full citation provenance and documented thresholds
Spanning foundational tremor physiology (1981) through current digital biomarker validation (2025)
Preliminary Clinical Evidence
Early validation data demonstrating metric discrimination between clinical populations. Prospective validation study designed to establish full psychometric properties.
Cross-Device Validation
N=40 (15 healthy controls, 25 PD patients) on Wacom digitizer hardware. Key motor metrics showed strong separation between groups:
Preliminary data. Adapted from published Turkish dataset.
Published Literature Support
Key psychometric properties from the published literature underlying the platform:
Metrics from published studies mapped to NeuroQuantix platform.
Prospective Validation Study
A prospective, multi-site, observational study designed to establish the full psychometric properties of the NeuroQuantix Spiral Analysis Platform as a Clinical Outcome Assessment for movement disorders.
Academic Sites
Primary Endpoints
Collaborate with us
We are actively seeking research partnerships to expand the evidence base for digital neuroscience assessment. Two ways to get involved:
Join the Validation Study
Our multi-site validation study (N=300, 4 academic centers, Smart IRB) is designed to establish the full psychometric properties of the NeuroQuantix platform. We welcome academic sites with movement disorder patient populations and established research infrastructure.
Discuss Site ParticipationUse NeuroQuantix in Your Research
Investigators running grant-funded or investigator-initiated studies can integrate NeuroQuantix or FaceWise as digital endpoints. We provide technical support, data export configuration, and co-authorship opportunities for collaborative research.
Explore Research UseInterested in the evidence base?
Request a detailed technical brief, discuss the validation study design, or explore how NeuroQuantix can serve as an endpoint in your clinical program.